Proposed Data Collection Submitted for Public Comment and Recommendations, 79922-79923 [2024-22477]

Download as PDF 79922 Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2024–22476 Filed 9–30–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–24–1046; Docket No. CDC–2024– 0074] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Monitoring Activities. This data collection is designed to systematically collect information about implementation, including delivery of screening and follow-up clinical services, and outcomes of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). DATES: CDC must receive written comments on or before December 2, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2024– 0074 by either of the following methods: • Federal eRulemaking Portal: www.regulations.gov. Follow the instructions for submitting comments. • Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to www.regulations.gov. Please note: Submit all comments through the Federal eRulemaking portal khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:42 Sep 30, 2024 Jkt 265001 (www.regulations.gov) or by U.S. mail to the address listed above. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329; Telephone: 404–639–7570; Email: omb@ cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. The OMB is particularly interested in comments that will help: 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; 2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; 3. Enhance the quality, utility, and clarity of the information to be collected; 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and 5. Assess information collection costs. Proposed Project National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Monitoring Activities (OMB Control No. 0920–1046, Exp. 03/31/2025)— Revision—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 Background and Brief Description CDC is requesting a Revision of the information collection titled National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Monitoring Activities (OMB Control No. 0920–1046). The information collection consists of an annual NBCCEDP survey, baseline and annual clinic-level data collection, a quarterly program update (QPU) tool, a service delivery projection worksheet, and minimum data elements (MDEs). CDC proposes revisions to the Annual NBCCEDP Survey, clinic-level data collection tool and QPU, and continued use of the service delivery projection worksheet and MDEs with no changes. The number of respondents will increase from 70 to 71 and the total estimated annualized burden will decrease from 1,220 hours to 1,162 hours. Breast and cervical cancers are prevalent among U.S. women. In 2021, the U.S. experienced 272,454 new cases and 42,211 deaths as a result of breast cancer, as well as 12,536 new cases and 4,051 deaths as a result of cervical cancer. Evidence shows that deaths from both breast and cervical cancers can be avoided by increasing screening services—mammography, pap, and human papillomavirus (HPV) tests— among women. However, in 2021, approximately one quarter of adults were not up to date with breast and/or cervical cancer screening, and screening was underutilized among women who are under- or uninsured, have no regular source of healthcare, or who recently immigrated to the U.S. As a longstanding priority within chronic disease prevention, CDC focuses on increasing access to these cancer screenings, particularly among women who may be at increased risk. To improve access to cancer screening, Congress passed the Breast and Cervical Cancer Mortality Prevention Act of 1990 (Pub. L. 106– 354), which directed CDC to create the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). The NBCCEDP currently provides funding to 71 recipients under ‘‘Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations (DP22–2202).’’ NBCCEDP awardees include states or their bona fide agents; U.S. territories; and tribes or tribal organizations. The purpose of NBCCEDP is to increase breast and cervical cancer screening rates among women residing within defined geographical locations (as determined by the funded program) who are at or below 250% of the federal poverty level; aged 50–75 years for breast cancer E:\FR\FM\01OCN1.SGM 01OCN1 79923 Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices services, and aged 21–64 years for cervical cancer services; and under- or uninsured. CDC proposes revisions to three of the previously approved information collection instruments: Annual NBCCEDP Survey—This instrument collects program-level information annually to monitor recipients’ challenges, external funding sources, partnerships, and EBI implementation. The survey has been revised to include new survey questions to improve data quality for items related to partnership activities and recipients’ requirements for patients’ payments towards screening services, as well as the removal of a COVID–19 related question. Clinic-Level Data Collection Tool— This instrument collects clinic-level data at baseline and annually to assess health system, clinic, and patient population characteristics; monitoring and quality improvement activities; EBI implementation; and baseline or annual current best practices for demographic questions related to sexual orientation and gender identity (SOGI) and race and ethnicity (R/E) at this time. However, CDC plans to revise information collections that include demographic items to align with HHS’ SOGI and R/ E guidelines for the next funding cycle beginning in 2027. The proposed information collections will allow CDC to better gauge progress in meeting NBCCEDP program goals and monitor implementation activities, evaluate outcomes, and identify awardee technical assistance needs. In addition, findings will inform program improvement and help identify successful activities that need to be maintained, replicated, or expanded. OMB approval is requested for three years. CDC requests OMB approval for an estimated 1,162 annual burden hours. Participation is required for NBCCEDP awardees. There are no costs to respondents other than their time. screening rates. This tool has been revised to remove COVID–19 related variables and update response options for the measures used to report breast and cervical cancer screening rates. QPU—This instrument collects program-level data four times per year to monitor award spending, service delivery, staff vacancies, program challenges and successes, and TA needs. This instrument has been revised to include two optional open-ended items to allow recipients to provide context to reported service delivery and spending data only if needed. CDC proposes continued use of the remaining two information collections; Service Delivery Project Worksheet and the MDEs, which have not been changed. To maximize consistency in our routine data collections for the current NBCCEDP funding cycle, CDC has not revised NBCCEDP information collections to align with the Department of Health and Human Services (HHS)’ ESTIMATED ANNUALIZED BURDEN HOURS Form name NBCCEDP Awardees ....................... Annual NBCCEDP Survey ............... NBCCEDP Clinic-level Information Collection Instrument—Breast. NBCCEDP Clinic-level Information Collection Instrument—Cervical. Quarterly Program Update ............... Service Delivery Projection Worksheet. MDEs ................................................ Total ........................................... ........................................................... Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2024–22477 Filed 9–30–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention khammond on DSKJM1Z7X2PROD with NOTICES Number of respondents Type of respondents [60Day—24–24IW; Docket No. CDC–2024– 0070] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: VerDate Sep<11>2014 17:42 Sep 30, 2024 Jkt 265001 ACTION: 1 6 46/60 40/60 54 284 71 6 40/60 284 71 71 4 1 22/60 29/60 151 34 71 2 150/60 355 ........................ ........................ ........................ 1,162 Notice with comment period. The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Becton Dickinson BACTECTM Blood Culture Media Bottles Shortage Impact Questionnaire, which will assess the impact of the Becton Dickinson (BD) BACTECTM blood culture media bottles supply shortage on individual facilities and how CDC NHSN bloodstream infection surveillance might be affected. Frm 00039 Fmt 4703 Total burden (in hours) 71 71 SUMMARY: PO 00000 Average burden per response (in hours) Number of responses per respondent Sfmt 4703 CDC must receive written comments on or before December 2, 2024. DATES: You may submit comments, identified by Docket No. CDC–2024– 0070 by either of the following methods: • Federal eRulemaking Portal: www.regulations.gov. Follow the instructions for submitting comments. • Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to www.regulations.gov. Please note: Submit all comments through the Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the address listed above. ADDRESSES: E:\FR\FM\01OCN1.SGM 01OCN1

Agencies

[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Pages 79922-79923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22477]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-24-1046; Docket No. CDC-2024-0074]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
federal agencies the opportunity to comment on a continuing information 
collection, as required by the Paperwork Reduction Act of 1995. This 
notice invites comment on a proposed information collection project 
titled National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) Monitoring Activities. This data collection is designed to 
systematically collect information about implementation, including 
delivery of screening and follow-up clinical services, and outcomes of 
the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP).

DATES: CDC must receive written comments on or before December 2, 2024.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0074 by either of the following methods:
     Federal eRulemaking Portal: www.regulations.gov. Follow 
the instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS H21-8, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to www.regulations.gov.
    Please note: Submit all comments through the Federal eRulemaking 
portal (www.regulations.gov) or by U.S. mail to the address listed 
above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Jeffrey M. Zirger, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected;
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses; and
    5. Assess information collection costs.

Proposed Project

    National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) Monitoring Activities (OMB Control No. 0920-1046, Exp. 03/31/
2025)--Revision--National Center for Chronic Disease Prevention and 
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention 
(CDC).

Background and Brief Description

    CDC is requesting a Revision of the information collection titled 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) 
Monitoring Activities (OMB Control No. 0920-1046). The information 
collection consists of an annual NBCCEDP survey, baseline and annual 
clinic-level data collection, a quarterly program update (QPU) tool, a 
service delivery projection worksheet, and minimum data elements 
(MDEs). CDC proposes revisions to the Annual NBCCEDP Survey, clinic-
level data collection tool and QPU, and continued use of the service 
delivery projection worksheet and MDEs with no changes. The number of 
respondents will increase from 70 to 71 and the total estimated 
annualized burden will decrease from 1,220 hours to 1,162 hours.
    Breast and cervical cancers are prevalent among U.S. women. In 
2021, the U.S. experienced 272,454 new cases and 42,211 deaths as a 
result of breast cancer, as well as 12,536 new cases and 4,051 deaths 
as a result of cervical cancer. Evidence shows that deaths from both 
breast and cervical cancers can be avoided by increasing screening 
services--mammography, pap, and human papillomavirus (HPV) tests--among 
women. However, in 2021, approximately one quarter of adults were not 
up to date with breast and/or cervical cancer screening, and screening 
was underutilized among women who are under- or uninsured, have no 
regular source of healthcare, or who recently immigrated to the U.S. As 
a longstanding priority within chronic disease prevention, CDC focuses 
on increasing access to these cancer screenings, particularly among 
women who may be at increased risk.
    To improve access to cancer screening, Congress passed the Breast 
and Cervical Cancer Mortality Prevention Act of 1990 (Pub. L. 106-354), 
which directed CDC to create the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP). The NBCCEDP currently provides 
funding to 71 recipients under ``Cancer Prevention and Control Programs 
for State, Territorial, and Tribal Organizations (DP22-2202).'' NBCCEDP 
awardees include states or their bona fide agents; U.S. territories; 
and tribes or tribal organizations. The purpose of NBCCEDP is to 
increase breast and cervical cancer screening rates among women 
residing within defined geographical locations (as determined by the 
funded program) who are at or below 250% of the federal poverty level; 
aged 50-75 years for breast cancer

[[Page 79923]]

services, and aged 21-64 years for cervical cancer services; and under- 
or uninsured.
    CDC proposes revisions to three of the previously approved 
information collection instruments:
    Annual NBCCEDP Survey--This instrument collects program-level 
information annually to monitor recipients' challenges, external 
funding sources, partnerships, and EBI implementation. The survey has 
been revised to include new survey questions to improve data quality 
for items related to partnership activities and recipients' 
requirements for patients' payments towards screening services, as well 
as the removal of a COVID-19 related question.
    Clinic-Level Data Collection Tool--This instrument collects clinic-
level data at baseline and annually to assess health system, clinic, 
and patient population characteristics; monitoring and quality 
improvement activities; EBI implementation; and baseline or annual 
screening rates. This tool has been revised to remove COVID-19 related 
variables and update response options for the measures used to report 
breast and cervical cancer screening rates.
    QPU--This instrument collects program-level data four times per 
year to monitor award spending, service delivery, staff vacancies, 
program challenges and successes, and TA needs. This instrument has 
been revised to include two optional open-ended items to allow 
recipients to provide context to reported service delivery and spending 
data only if needed.
    CDC proposes continued use of the remaining two information 
collections; Service Delivery Project Worksheet and the MDEs, which 
have not been changed. To maximize consistency in our routine data 
collections for the current NBCCEDP funding cycle, CDC has not revised 
NBCCEDP information collections to align with the Department of Health 
and Human Services (HHS)' current best practices for demographic 
questions related to sexual orientation and gender identity (SOGI) and 
race and ethnicity (R/E) at this time. However, CDC plans to revise 
information collections that include demographic items to align with 
HHS' SOGI and R/E guidelines for the next funding cycle beginning in 
2027.
    The proposed information collections will allow CDC to better gauge 
progress in meeting NBCCEDP program goals and monitor implementation 
activities, evaluate outcomes, and identify awardee technical 
assistance needs. In addition, findings will inform program improvement 
and help identify successful activities that need to be maintained, 
replicated, or expanded.
    OMB approval is requested for three years. CDC requests OMB 
approval for an estimated 1,162 annual burden hours. Participation is 
required for NBCCEDP awardees. There are no costs to respondents other 
than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
NBCCEDP Awardees..............  Annual NBCCEDP                71               1           46/60              54
                                 Survey.
                                NBCCEDP Clinic-               71               6           40/60             284
                                 level
                                 Information
                                 Collection
                                 Instrument--Bre
                                 ast.
                                NBCCEDP Clinic-               71               6           40/60             284
                                 level
                                 Information
                                 Collection
                                 Instrument--Cer
                                 vical.
                                Quarterly                     71               4           22/60             151
                                 Program Update.
                                Service Delivery              71               1           29/60              34
                                 Projection
                                 Worksheet.
                                MDEs............              71               2          150/60             355
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............           1,162
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health 
Ethics and Regulations, Office of Science, Centers for Disease Control 
and Prevention.
[FR Doc. 2024-22477 Filed 9-30-24; 8:45 am]
BILLING CODE 4163-18-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.